Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD: GlobalData Read more
GSK’s Nucala highlights IL-5 inhibition in reducing COPD exacerbations in eosinophilic patients: GlobalData Read more
Three CAR-T therapies forecasted to capture over 70 per cent of T-Cell immunotherapy market in 2025 Read more
Global divide emerges among physicians over patient choice in biologics vs. biosimilars, reveals GlobalData Read more